Chemoinformaics analysis of Isofraxidin-7-O-Alpha-L-Glucoside
| Molecular Weight | 384.337 | nRot | 5 |
| Heavy Atom Molecular Weight | 364.177 | nRig | 18 |
| Exact Molecular Weight | 384.106 | nRing | 3 |
| Solubility: LogS | -2.107 | nHRing | 2 |
| Solubility: LogP | -0.575 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 2 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 47 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 27 | No. of Aromatic Carbocycles | 1 |
| nHetero | 10 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 20 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 17 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 10 |
| No. of Oxygen atom | 10 | No. of Arom Bond | 11 |
| nHA | 10 | APOL | 49.7459 |
| nHD | 4 | BPOL | 29.6121 |
| QED | 0.473 |
| Synth | 3.801 |
| Natural Product Likeliness | 1.872 |
| NR-PPAR-gamma | 0.022 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.001 |
| Pgp-sub | 0.606 |
| HIA | 0.615 |
| CACO-2 | -5.643 |
| MDCK | 0.0000647 |
| BBB | 0.731 |
| PPB | 0.376668 |
| VDSS | 0.837 |
| FU | 0.401308 |
| CYP1A2-inh | 0.028 |
| CYP1A2-sub | 0.726 |
| CYP2c19-inh | 0.011 |
| CYP2c19-sub | 0.716 |
| CYP2c9-inh | 0.001 |
| CYP2c9-sub | 0.371 |
| CYP2d6-inh | 0.005 |
| CYP2d6-sub | 0.274 |
| CYP3a4-inh | 0.006 |
| CYP3a4-sub | 0.037 |
| CL | 3.371 |
| T12 | 0.532 |
| hERG | 0.045 |
| Ames | 0.285 |
| ROA | 0.211 |
| SkinSen | 0.034 |
| Carcinogencity | 0.53 |
| EI | 0.007 |
| Respiratory | 0.016 |
| NR-Aromatase | 0.615 |
| Antiviral | Yes |
| Prediction | 0.613776 |